MALVERN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the closing of its previously announced underwritten public offering of 30,434,783 shares of its common stock. Each share of common stock was sold at a price to the public of $1.15 per share. The gross proceeds to the Company from the offering were approximately $35 million, before deducting und ...

MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the pricing of its underwritten public offering of 30,434,783 shares of its common stock at an offering price of $1.15 per share of common stock for gross proceeds of $35 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ocugen ...

MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the pricing of its underwritten public offering of 30,434,783 shares of its common stock at an offering price of $1.15 per share of common stock for gross proceeds of $35 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ocugen ...

MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it has commenced an underwritten public offering (the "offering") of its common stock. In addition, Ocugen expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock to be sold in the public offering at the pub ...

Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugen investor site. Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact ...

MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's second quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Thursday, August 8, 2024. Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for internat ...

Company Overview - Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients globally [17] - The company is advancing research in infectious diseases and orthopedic diseases to address unmet medical needs [17] Product Development - Ocugen has initiated a Phase 2 clinical trial for OCU410, a novel modifier gene therapy candidate for geographic atrophy (GA), which is an advanced stage of dry age-related macular degeneration (dAMD) [14][15] - The ArMaDa Phase 1/2 clinical trial for OCU410 will assess the safety of unilateral subretinal administration in subjects with GA, consisting of a multicenter, open-label, dose-escalation study [7][11] - OCU410 utilizes an adeno-associated virus (AAV) platform to deliver the RORA gene, which plays a role in lipid metabolism and has anti-inflammatory properties [12] Market Context - Geographic atrophy affects approximately 1 million people in the United States, while dry age-related macular degeneration affects around 10 million Americans and over 266 million people worldwide [14][16] - Current FDA-approved anti-complement therapies for GA target only one pathway, providing limited benefits and requiring multiple intravitreal injections over several years [1]

• Initiated Phase 2 clinical trial "Currently, there are two FDA approved anti-complement therapies for GA, which targets only one pathway for a disease that has a multifactorial and complex etiology," said Majda Hadziahmetovic, MD, Associate Professor of Ophthalmology, Vitreoretinal Diseases and Surgery, Duke University Eye Center, and the lead investigator for the OCU410 Phase 1/2 trial. "Though these treatments are a significant milestone, they provide limited benefits and involve a continuous regimen of ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Ocugen (OCGN) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Over the past three months, the Zacks Consensus Estimate for OCGN's full-year earnings has moved 9.2% higher. This shows that analyst sentiment has improved and the company's earnings ou ...

MALVERN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial recently convened and approved to proceed with dosing the high dose of OCU410ST in the dose-escalation phase of the study. OCU410ST (AAV5-hRORA) is a modifier gene therapy candidate ...